Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 20, 2022 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead

BURNABY, British Columbia, July 20, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
March 21, 2022 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Closes USD$12M Equity Financing

BURNABY, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
July 13, 2021 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress

VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of...
June 23, 2021 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment

VANCOUVER, British Columbia, June 23, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
June 09, 2021 09:00 ET | Source: Qu Biologics, Inc.

Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021

VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
May 12, 2021 09:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis

VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
January 04, 2021 09:00 ET | Source: Qu Biologics, Inc.

Positive Signals for Endoscopic and Histologic Response in Patients with Crohn’s Disease Treated with Qu Biologics’ QBECO

VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
December 18, 2020 13:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform

VANCOUVER, British Columbia, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
December 09, 2020 06:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Completes $8M Financing

VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
August 24, 2020 06:00 ET | Source: Qu Biologics, Inc.

Qu Biologics is pleased to announce the appointment of Karn Manhas to Qu’s Board of Directors

VANCOUVER, British Columbia, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...

Next Page keyboard_arrow_right